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The generation of reactive oxygen species is a central feature of
inflammation that results in the oxidation of host phospholipids.
Oxidized phospholipids, such as 1-palmitoyl-2-arachidonyl-sn-
glycero-3-phosphorylcholine (OxPAPC), have been shown to
inhibit signaling induced by bacterial lipopeptide or lipopolysac-
charide (LPS), yet themechanisms responsible for the inhibitionof
Toll-like receptor (TLR) signaling by OxPAPC remain incom-
pletely understood. Here, we examined the mechanisms by which
OxPAPCinhibitsTLRsignaling inducedbydiverse ligands inmac-
rophages, smoothmusclecells, andepithelial cells.OxPAPCinhib-
ited tumor necrosis factor- production, IB degradation, p38
MAPK phosphorylation, and NF-B-dependent reporter activa-
tion induced by stimulants of TLR2 and TLR4 (Pam3CSK4 and
LPS) but not by stimulants of other TLRs (poly(IC), flagellin, lox-
oribine, single-stranded RNA, or CpG DNA) in macrophages and
HEK-293 cells transfected with respective TLRs and significantly
reduced inflammatory responses in mice injected subcutaneously
or intraperitoneally with Pam3CSK4. Serum proteins, including
CD14 andLPS-binding protein, were identified as key targets for
the specificity of TLR inhibition as supplementationwith excess
serum or recombinant CD14 or LBP reversed TLR2 inhibition
by OxPAPC, whereas serum accessory proteins or expression of
membrane CD14 potentiated signaling via TLR2 and TLR4 but
not other TLRs. Binding experiments and functional assays
identified MD2 as a novel additional target of OxPAPC inhibi-
tion of LPS signaling. Synthetic phospholipid oxidation prod-
ucts 1-palmitoyl-2-(5-oxovaleryl)-sn-glycero-3-phosphocho-
line and 1-palmitoyl-2-glutaryl-sn-glycero-3-phosphocholine
inhibited TLR2 signaling from 30 M. Taken together, these
results suggest that oxidized phospholipid-mediated inhibition
of TLR signaling occurs mainly by competitive interaction with
accessory proteins that interact directly with bacterial lipids to
promote signaling via TLR2 or TLR4.
The generation of reactive oxygen species by phagocytes is
central to the antimicrobial effectiveness of the inflammatory
response. Activated polymorphonuclear cells in particular
express enzymes such as NADPH oxidase and myeloperoxi-
dase, which together generate a range of oxidants, including
superoxide, hydrogen peroxide, and hypochlorous acid, each of
which may be released from these cells to cause oxidative dam-
age not only to invading microorganisms but also to host mol-
ecules in surrounding tissues (1). Phospholipids containing
polyunsaturated fatty acid chains, such as the abundant phos-
pholipid 1-palmitoyl-2-arachidonyl-sn-glycero-3-phosphoryl-
choline (PAPC),2 are particularly susceptible to oxidation by
such mediators (2, 3), and products of PAPC oxidation have
been shown to accumulate at sites of inflammation (3–6) and in
cells treated with stimulants such as IL-1, TNF-, or long
wave ultraviolet radiation (7–9). Oxidation of PAPC leads to
the formation of a mixture of products, ranging from epoxyiso-
prostanes to truncated chain derivatives that are collectively
termed OxPAPC, which is a widely used model for the investi-
gation of oxidized phospholipid (OxPL) function (10–12).
To date, much research has focused on the potential of
OxPLs to augment inflammatory events bymechanisms such as
the up-regulation of IL-8 or promotion of monocyte binding to
endothelial cells, particularly in the context of the chronic
inflammatory processes of atherosclerosis (6, 13). However,
OxPLs have also been shown to possess diverse anti-inflamma-
tory properties. For example, OxPAPC was shown to induce
peroxisome proliferator activated receptor--dependent sig-
naling, expression of heme oxygenase-1 andMAP kinase phos-
phatase-1, each of which has established antiinflammatory
properties (14–16). More directly, it was shown that OxPAPC
potently inhibits inflammation-related tissue damage and
death caused by endotoxemia in mice (17). As a result, it has
been proposed that host recognition of OxPLs may represent
an endogenous feedback mechanism that serves to limit the
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potential damage caused by inflammation-induced oxidants
(17).
Such feedback mechanisms are now understood to play key
roles in the resolution of inflammation, a process that is
increasingly viewed as active and well orchestrated. Examina-
tion of resolving exudates has identified a range of lipid-based
mediators of resolution, such as the lipoxins and resolvins,
which each promote resolution (18, 19). These agents are cre-
ated largely by the enzymatic oxidation of unsaturated fatty
acids, such as arachidonic, eicosapentaenoic, and docosahexae-
noic acids via the action of cyclooxygenase-2 and lipoxygenases
(20).However, despite the recent progress in understanding the
roles for enzymatically oxidized lipids in resolution, the poten-
tial role of oxidized lipids created by nonenzymatic routes, such
as by reactive oxygen species-mediated peroxidation, has
received comparatively little attention.
Because stimulation of Toll-like receptor (TLR) signaling has
been shown to play a central role in the induction of inflamma-
tion, oxidant release, and tissue damage in many different dis-
ease models (21–23), it is notable that OxPAPC potently inhib-
its the ability of LPS to stimulate TLR4-dependent signaling in
macrophages, dendritic cells, and endothelial cells (3, 10, 11, 17,
24, 25). The mechanisms by which OxPAPC inhibits LPS sig-
naling are currently under debate, and numerous potential
models have been put forward. For example, it has been sug-
gested that the generation of cAMP in response to products of
phospholipid oxidation could inhibit NF-B-induced gene
transcription stimulated by LPS in endothelial cells (10). More
recently, it was shown that OxPLs can bind to CD14 and LPS-
binding protein (LBP), both of which serve to enhance cellular
sensitivity to LPS (17). Alternatively, it has been suggested that
the capacity of OxPLs to deplete cellular cholesterol and
thereby disrupt lipid-rafts or caveolae could also contribute to
TLR inhibition, on the assumption that recruitment of TLRs to
rafts may be a requirement for effective TLR-signaling (11, 26).
Finally, using synthetic derivatives of OxPLs, it was shown that
the production of ceramide via neutral sphingomyelinase acti-
vation may also contribute to inhibition of LPS signaling and
that phospholipid oxidation products containing ,-unsatur-
ated carboxylic acids are among the most efficient inhibitors of
LPS signaling deriving from PAPC oxidation (27).
However, despite this progress, very little has been learned
about the mechanisms by which OxPLs may inhibit signaling
induced by other TLRs. Although it was shown that treatment
of macrophages with OxPAPC reduces the secretion of IL-8 in
response to the TLR2 ligand Mycobacterium tuberculosis
lipoprotein (11) and that high concentrations of OxPAPC may
reduce the amount of TNF- secreted in response to the TLR9
agonist CpG DNA (24), no studies have yet addressed the
mechanisms by which these or other TLRs beyond TLR4 are
inhibited by OxPLs. We, therefore, aimed to establish the
potential of OxPLs to inhibit signaling induced by other TLRs
and to investigate themechanisms responsible for these effects.
EXPERIMENTAL PROCEDURES
Reagents—PAPC, methyl--cyclodextrin (MBCD), nystatin,
MTT,DMEM,RPMI, and fetal calf serumwere purchased from
Sigma. Escherichia coli R1 LPS was a kind gift of Professor Ian
Poxton (University of Edinburgh). TLR ligands Pam3CSK4,
poly(IC), Bacillus subtilis flagellin, loxoribine, ssRNA, and
endotoxin-free CpG DNA were from Invivogen. Recombinant
soluble CD14 was from R&D Systems. LBP purified from
human plasma was obtained from Hycult Biotechnology. Syn-
thetic 1-palmitoyl-2-(5-oxovaleryl)-sn-glycero-3-phosphocho-
line (POVPC) and 1-palmitoyl-2-glutaryl-sn-glycero-3-phos-
phocholine (PGPC) were obtained from Avanti Polar Lipids.
Endotoxin contamination of reagents was ruled out by the use
of limulus amebocyte lysate assays (Quadratech) or challenge of
TLR4-transfected HEK-293 cells. OxPAPCwas prepared by air
oxidation of native PAPC as described previously (4). Briefly, 1
mg of PAPC in chloroform was evaporated to dryness under
nitrogen in a glass tube. The lipid filmwas then exposed to air in
darkness for 72 h before resuspension to 2mg/ml in chloroform
and stored under nitrogen at80 °C. The extent of oxidation of
PAPC was monitored by electrospray mass spectrometry and
showed a similar profile to that described previously (4, 28).
Aliquots of stockOxPAPCwere dried under nitrogen in Eppen-
dorf tubes immediately before use and vortexed into pre-
warmed medium (37 °C) for 30 s before the addition to cells.
Cells and Media—The human monocytic THP-1 cell-line
(ECACC 88081201) was cultured in RPMI, 10% FCS. Before
challenge in all experiments, THP-1 cells were treated with 100
nM phorbol 12-myristate 13-acetate for 72 h to allow differen-
tiation to adherent macrophages. Murine J774A.1 macro-
phages (ECACC 91051511) were cultured in DMEM, 10% FCS.
Human epithelial HEK-293 cells (ECACC 85120602) and the
transformed human arterial smooth muscle (HASMC) cell line
(ACBRI #443, Applied Cell Biology Research Institute, Kirk-
land, WA) were maintained in DMEM, 10% FCS.
Challenge of Cells with Pathogen-associated Molecular Pat-
terns (PAMPs)—THP-1 macrophages were challenged with
mediumalone (DMEM, 1%FCS) or 1–100 ng/ml Pam3CSK4, or
0.1–10 ng/ml LPS in the presence or absence of 30 g/ml
OxPAPC. J774A.1 macrophages were challenged with medium
alone or 250–1000 ng/mlB. subtilis flagellin with or without 30
g/ml OxPAPC. HASMC were challenged with medium alone
(DMEM, 1% FCS) or 10–1000 ng/ml poly(IC). Alternatively,
cells were challenged with 10 ng/ml Pam3CSK4, 10 ng/ml LPS,
500 ng/ml flagellin, or 1 g/ml poly(IC) with 0–30 g/ml
OxPAPC. In other experiments J774A.1 cells were challenged
with 1 mM loxoribine, 2.5 g/ml ssRNA, 10 g/ml CpG DNA
with or without 30 g/ml OxPAPC. Supernatants from chal-
lenged cells were assessed for IL-8 content by enzyme-linked
immunosorbent assay (R&DDuoSet) after 18 h or TNF- con-
tent (R&D DuoSet or L929 bioassay (29)) after 4 h. For serum
dependence experiments, macrophages were washed three
times in serum-free medium before challenge with PAMPs at
the indicated concentrations in serum-free medium or serum
supplemented with 1% FCS.
Western Blotting—To investigate the impact of OxPAPC on
intracellular signaling pathways stimulated by TLRs, THP-1
macrophages were plated in 12-well plates (5  105 cells per
well) and challenged with medium alone, 250 ng/ml TNF-
(Peprotech), or 10 ng/ml LPS with or without 50 g/ml
OxPAPC co-treatment for 20 min before lysis. Alternatively,
J774A.1 cells were challenged with medium alone (DMEM, 1%
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FCS), 10 ng/ml Pam3CSK4, 10 ng/ml LPS, 1 mM loxoribine, or
10 g/ml CpG DNA with or without 50 g/ml OxPAPC co-
treatment for 20 min before lysis. Samples were boiled with 0.1 M
dithiothreitol and separated by reducing denaturing PAGE
before blotting to nitrocellulose. Blots were then probed with
antibodies to IB (SantaCruz), phospho-p38MAPK (Cell Sig-
naling), or glyceraldehyde-3-phosphate dehydrogenase (Santa
Cruz) and visualized with enhanced chemiluminescence kit
(Pierce).
Reporter Assays—For transfection assays, HEK-293 cells
were plated in 96-well plates at 2 104 cells per well and trans-
fected after 24 h using Genejuice (Novagen) according to the
manufacturer’s instructions. Amounts of construct per well
were 30 ng of human TLRs 2, 4 (co-expressing MD-2), or 5
(Invivogen), 30 ng of pCD14, 20 ng of transfection efficiency
control renilla luciferase-reporter construct (pRL-TK), and 10
ng of firefly luciferase-reporter construct driven by NF-B-de-
pendent promoter (pELAM) cloned into pGL3 (Promega) as
described previously (28), with the balancemade upwith empty
pCDNA3. Cells were grown for 2–3 days post-transfection
before an 18 h challenge with PAMPs in the presence or
absence of 10–30 g/ml OxPAPC. Reporter levels were nor-
malized to co-transfected renilla reporter expression. Promoter
expression is represented as -fold induction relative to cells
cultured inmedium aloneS.D. To determine requirements of
membrane CD14 expression, cells were transfected with TLRs
30 ng per well of pCD14 or pCDNA3. All constructs used
other than pRL-TK were of human origin.
Serum Lipid Shuttle Protein Experiments—HEK-293 cells
transfected with TLR2 or TLR4MD2 andNF-B reporter were
challenged with 100 ng/ml Pam3CSK4 or 1 ng/ml LPS with or
without 30g/mlOxPAPC inDMEMsupplementedwith 1, 10,
or 30% serum. Alternatively HEK-293-TLR2 cells were chal-
lenged with 100 ng/ml Pam3CSK4 in the presence or absence of
0.5 or 2.0 g/ml recombinant
sCD14 (R&D) or 0.3 or 1.0 g/ml
LBP purified from human plasma
(Hycult biotechnology). After 18 h,
expression of reporter was meas-
ured by luminometry as described
above.
Membrane Disruption and Cell
Viability Assays—Membrane cho-
lesterol disrupting agents MBCD,
nystatin, or OxPAPC were added to
THP-1 macrophages at 0.032–10
mM, 3.2–1000 M, or 10–300
g/ml, respectively. 18 h later, cellu-
lar viability was monitored by MTT
assay as described previously (30).
Alternatively, THP-1 macrophages
were challenged with 10 ng/ml
Pam3CSK4 or LPS in the presence of
MBCD or nystatin at 300–1200 or
1–5 M, respectively. Supernatant
TNF- was measured at 4 h as
described above.
MD2 Binding Assays—Soluble
MD2 protein was prepared by transfection of HEK-293 cells
plated in 12-well plates (2  105 cells per well) with 1 g per
well of a construct expressing FLAG-His-tagged MD2
(pEFBOS-MD2, a kind gift of Prof. K. Miyake). MD-2-containing
supernatant was collected at 48 h. For MD2 immobilization,
100l per well of anti-FLAGmonoclonal antibody (Sigma) was
added to high binding immunoassay strips (Nunc Immuno-
module) before washing 3 times in phosphate-buffered saline,
0.05%Tween and addingMD-2 supernatant for 2 h.Wells were
then washed, and 500 ng/ml biotinylated LPS (Invivogen) was
added in the presence of 0, 10, or 25 g/ml native or oxidized
PAPC for a further 2 h to allow binding to immobilized MD2.
Wells werewashed once again, and bound biotinylated LPSwas
measured by the addition of streptavidin-horseradish peroxi-
dase (HRP) and colorimetric determination at 450 nm after the
addition of HRP substrate 3,3,5,5-tetramethylbenzidine. For
MD2 co-precipitation experiments, MD2 supernatant was
incubated with 1 g/ml biotinylated LPS with or without 15
min preincubation with 10 g/ml unlabeled LPS or 50 g/ml
OxPAPC. Streptavidin-agarose beads (Sigma) were then added
to mixtures and rotated overnight at 4 °C. Beads were pelleted
by centrifugation (13,000  g, 10 min), resuspended in SDS-
PAGE loading buffer, boiled, and separated on 15% SDS-PAGE
gels before transfer to nitrocellulose blots. Precipitated MD2
was visualized by probing blots with anti-FLAG antibody
(Sigma). To assess functional effects of OxPAPC effects on
MD2, MD2 supernatant was preincubated with 50 g/ml
OxPAPC for 30 min before the addition of 100 ng/ml LPS.
Supernatants were then added to HEK-293 cells transfected
with TLR4 and reporter constructs without MD2 cotransfec-
tion. Activation of NF-B-dependent reporter wasmeasured at
18 h as described above.
Animal Experiments—8-Week-old male BALB/c mice
were injected subcutaneously with 50 l of saline, 2.5 g of
FIGURE 1. Effect of OxPAPC on bacterial lipopeptide-, LPS-, and flagellin-induced TNF- production.
Human THP-1 macrophages (A, B, D, and E) or murine J774A.1 macrophages (C and F) were challenged with
PAMPs in the presence or absence of OxPAPC, and the TNF- content of culture supernatants was measured
4h after challenge. Cellswere challengedwith the indicated concentrations of the TLR2 agonist Pam3CSK4, the
TLR4 agonist E. coli LPS, or the TLR5 agonist B. subtilis flagellin in the presence or absence of 30g/ml OxPAPC
(A–C). Alternatively, cellswere challengedwith100ng/mlPam3CSK4, 10ng/ml LPS, or 1g/ml flagellinwith the
indicated concentrations of OxPAPC (D–F). Results shown are means of triplicate culturesS.D. and are rep-
resentative of at least three similar experiments. **, p 0.01 versuswithout OxPAPC (ANOVA).
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Pam3CSK4, or 2.5 g of Pam3CSK4 with 7.5 g of OxPAPC
(n  3 per group). Skin around each injection site was
removed from killed animals after 24 h, and extent of inflam-
matory infiltrate was assessed by hematoxylin and eosin
staining. Polymorphonuclear granulocyte (PMN) infiltra-
tion into subcutaneous tissue was quantified by counting
PMNs present in low power fields of Sudan black-stained
sections. Alternatively, mice (n 4 per group) were injected
intraperitoneally with 200 l of saline, 10 g of Pam3CSK4,
or 10 g of Pam3CSK4 with 50 g OxPAPC. Cells were
counted in peritoneal lavage fluid (3 ml of phosphate-buff-
ered saline) after 24 h using a hemocytometer. All experi-
ments were carried out in accordance with the United King-
dom Home Office Guide on the Operation of Animals
(Scientific Procedures) Act 1986.
RESULTS
OxPAPC Inhibits Signaling viaTLR2andTLR4butNotOther
TLRs—To establish whether the ability of OxPLs to inhibit
TLR4 signaling extended to other TLRs, the capacity of
OxPAPC to modulate cytokine release induced by defined
PAMPs specific for other TLRs was assessed. As expected,
OxPAPC inhibited the production of TNF- by THP-1 macro-
phages in response to challenge with the TLR2 ligand
Pam3CSK4 or the TLR4 ligand E. coli LPS in a dose-dependent
manner, withmaximal inhibition occurring at 30g/ml (Fig. 1).
However, TNF- production in response to the TLR5 ligand
flagellin was found to be unaltered by OxPAPC treatment (Fig.
1). Similar results were obtained with primary human mono-
cyte-derived macrophages (not shown). TNF- production by
J774A.1 macrophages in response to the TLR7, TLR8, and
TLR9 ligands loxoribine, ssRNA, and CpG DNA, respectively,
was also unaltered by OxPAPC (Fig. 2). We found that human
and murine macrophages produced very little or no TNF- in
response to the TLR3 ligand poly(IC). However, poly(IC)
potently up-regulated the production of IL-8 by human aortic
smooth muscle cells, and this response was not significantly
altered by co-treatment with OxPAPC (Fig. 2). OxPAPC pre-
treatment of cells for 1 h before challenge also had no effect on
cytokine production in response to these PAMPs (data not
shown).
To examine whether the specificity of OxPAPC inhibition of
TLRs could be verified using alternative readouts of TLR-in-
duced signaling, the activation of NF-B dependent reporter
transcription was examined in HEK-293 cells transfected with
vector alone, TLR2, TLR5, or TLR4MD2. These experiments
were performed using a strain of HEK-293 that was found to
express low levels of TLR3 and were, therefore, responsive to
poly(IC) but which did not express transcripts for TLRs 2, 4, or
5 and were entirely insensitive to LPS, bacterial lipopeptide or
flagellin in the absence ofTLR transfection (Ref. 28 anddata not
shown). As expected, OxPAPC dose-dependently inhibited
TLR2- and TLR4-dependent induction of NF-B dependent
reporter activation in this system. However, TLR3- or TLR5-
dependent induction of NF-B was not altered by OxPAPC
treatment (Fig. 3). In agreement with previous findings (11, 17),
native (unoxidized) PAPC did not alter cytokine secretion or
NF-B reporter expression in response to PAMPs in these
experiments (data not shown).
OxPAPC Inhibition of TLR2 and TLR4 Signaling Occurs
Upstream of IB and p38 MAPK—To identify the point
within the TLR-signaling cascades that may be targeted by
OxPAPC for the specificity of TLR inhibition, PAMP-induced
phosphorylation of p38 MAP kinase and degradation of IB
was examined in THP-1 and J774A.1 macrophages. LPS-in-
duced degradation of IB in these cells was blocked by
OxPAPC treatment, whereas TNF- dependent IB degrada-
tion was unaffected by co-culture with OxPAPC, indicating
FIGURE 2. Effect of OxPAPC on cytokine responses to agonists of TLRs
3, 7, 8, and 9. HASMC were challenged with indicated concentrations of
the TLR3 ligand poly(IC) in the presence or absence of 30 g/ml OxPAPC
(A), or with 10g/ml poly(IC) and the indicated concentrations of OxPAPC
(B). Supernatant IL-8 was measured by enzyme-linked immunosorbent
assay at 18 h. C, J774A.1 macrophages were challenged with medium
alone (Ctrl), 10 ng/ml LPS, 1 mM loxoribine (Lox), 2.5 g/ml ssRNA, or 10
g/ml CpG DNA with or without 30 g/ml OxPAPC. Supernatant TNF-
content was measured 4 h after challenge. Results shown are means of
triplicate cultures  S.D. and are representative of at least two similar
experiments. n.s., not significant.
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that OxPAPC does not act as a nonspecific inhibitor of IB
degradation (Fig. 4A). Stimulation of cells with the TLR2 ligand
Pam3CSK4, like LPS, induced IB degradation and p38MAPK
phosphorylation, which were both inhibited by OxPAPC (Fig.
4B). However, IB degradation and p38 MAPK phosphoryla-
tion induced by ligands of TLRs 5, 7, or 9 (flagellin, loxoribine,
and CpG DNA, respectively) was unaffected by OxPAPC (Fig.
4, B andC), confirming that OxPAPC does not act as a nonspe-
cific inhibitor of IB degradation or p38 MAPK phosphoryl-
ation inmacrophages. This further suggests thatOxPAPC inhi-
bition of TLR2- and TLR4-dependent signaling may occur
upstream of these intracellular mediators. As before, native
(unoxidized) PAPC had no effect on PAMP signaling (not
shown).
Signaling via TLR2 and TLR4, but Not Other TLRs, Is
Serum-dependent—Because TLRs 5, 7, 8, and 9 share intra-
cellular signaling pathways that are thought to be very sim-
ilar to those of TLR2 (31), we sought alternative mechanisms
for the specificity of OxPAPC-mediated TLR inhibition.
Because it has been shown that both LPS- and lipopeptide-
induced cellular signaling is potentiated by serum-derived
lipid-shuttle proteins (32), we sought to determine whether
signaling via other TLRs may also require serum-derived
accessory molecules. Although production of TNF- by
J774A.1 macrophages in response to LPS and Pam3CSK4
treatment was serum-dependent, TNF- production in
response to flagellin, loxoribine, ssRNA, and CpG DNA was
found to be unaltered by the presence or absence of serum
supplementation (Fig. 5 and data not shown). HASMC pro-
duction of IL-8 in response to TLR3 stimulation with
poly(IC) was also unimpaired in
the absence of serum (Fig. 5).
Signaling via TLR2 and TLR4, but
Not TLR3 or TLR5, Is CD14-
dependent—Signaling via TLR2 and
TLR4 has been shown to be poten-
tiated by the presence of CD14,
which either in the soluble form
(sCD14) or in a glycosylphosphati-
dylinositol-anchored membrane-
bound form (mCD14), serves to cat-
alyze the transfer of lipophilic
PAMPs from bacterial membranes
or LBP to the TLR2 or TLR4MD2
receptor complexes (32, 33). To
determine whether CD14 may also
be required for signaling via other
TLRs, stimulation of an NF-B-de-
pendent reporter was examined in
the CD14-deficient HEK-293 cell
line transfected with TLRs with or
without a construct expressing
membrane CD14.When challenged
with PAMPs in the absence of
serum (and, hence, any exogenous
source of sCD14), co-expression of
mCD14markedly enhanced cellular
sensitivity to LPS and Pam3CSK4,
whereas it did not alter cellular sensitivity to the TLR3 and
TLR5 ligands poly(IC) or flagellin, respectively (Fig. 6).
OxPAPC Inhibition of TLR2 Signaling Is Dependent on Serum
Components Including CD14 and LBP—In the presence of 1%
serum, OxPAPC was found to be a potent inhibitor of TLR2-
and TLR4-dependent signaling in transfected HEK-293 cells
(Fig. 7). However, OxPAPC-mediated inhibition of TLR2 sig-
naling was reversed completely by supplementation with 30%
serum (Fig. 7A). Because OxPAPC has been shown to bind to
CD14 (17) and sCD14 has been shown to play a role in lipopep-
tide signaling (32, 34, 35), we examined whether supplementa-
tion of the culturemediumwith recombinant sCD14 alonemay
also reverse OxPAPC-induced inhibition of TLR2 signaling.
Consistent with a role for this protein, OxPAPC inhibition of
Pam3CSK4 signaling was reversed by sCD14 supplementation
in a dose-dependent fashion (Fig. 7C). Likewise, supplementa-
tion with exogenous human LBP also dose-dependently
reversed OxPAPC inhibition of TLR2-dependent signaling
(Fig. 7D), suggesting that both CD14 and LBPmay be targets of
OxPAPC inhibition of TLR2 signaling. Surprisingly, however,
OxPAPC-mediated inhibition of LPS-induced signaling could
not be reversed either by increased serum concentration or by
supplementation with exogenous recombinant sCD14 or
human LBP (Fig. 7B and data not shown).
Effects of Membrane-disrupting Agents on TLR Signaling—It
has been well established that after binding of LPS toMD2, the
stimulated TLR4MD2 complex co-localizes to lipid-raft mem-
brane fractions (26, 36). This observation has led to the sugges-
tion that TLR localization to lipid-rafts or raft-like caveolae
may be a requirement for effective LPS signaling and that
FIGURE 3. Effects of OxPAPC on TLR-dependent NF-B reporter activation. Late passage HEK-293 cells,
which expressed low levels of TLR3 transcripts but not mRNA for TLRs 2, 4, or 5 (data not shown), were
transfected with CD14, NF-B-sensitive reporter construct (pELAM), and transfection-efficiency control con-
struct (pRL-TK) alongwith additional TLR2 (A), no TLRs (B), TLR4MD2 (C), or TLR5 (D). After 48 h transfected cells
were challenged with respective ligands (100 ng/ml Pam3CSK4, 10 g/ml poly(IC), 10 ng/ml LPS, or 1 g/ml
flagellin) and 0–30 g/ml OxPAPC. NF-B reporter activation was measured at 18 h and is presented as -fold
induction relative to control cultures challenged inmedium alone. Means of triplicate cultures independently
normalized for transfection efficiency are presentedS.D. Results shown are representative of at least three
similar experiments. **, p 0.01 versus PAMP without OxPAPC (ANOVA).
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OxPAPC-mediated disruption of lipid-rafts may explain some
of the ability of OxPAPC to inhibit TLR signaling (11, 27). We,
therefore, aimed to examine further the potential of raft-dis-
rupting agents to inhibit TLR-dependent signaling. MTT
assays revealed that the two well established raft-disrupting
agents, nystatin andMBCD, induced a dose-dependent reduction
in cellular viability that was significant at concentrations higher
than around 10 M for nystatin or 1 mM for MBCD (Fig. 8A).
OxPAPC had no effect onmacrophage viability at concentrations
up to 50 g/ml, whereas 300 g/ml OxPAPC induced a marked
loss of cellular viability (Fig. 8B). When used at sublethal concen-
trations,neithernystatinnorMBCDinhibitedTLR2-orTLR4-de-
pendent induction of TNF- production in THP-1 macrophages
(Fig. 8, C and D). Inhibitors of established OxPAPC-induced sig-
naling pathways that could mediate anti-inflammatory effects in
cells, includingRpCAMPs,H-89,MK886, and sodiumorthovana-
date, also failed to reverse OxPAPC-mediated inhibition of LPS
signaling in macrophages (data not shown).
Effects of OxPAPC on LPS Binding to MD2—Because
OxPAPC-mediated inhibition of LPS signaling could not be
reversed by serum, CD14, or LBP and OxPAPC pretreated and
washed cells have been shown to remain unresponsive to LPS
(11), we next examined the possibility that a novel cellular tar-
get of OxPAPC may exist that is a component of the LPS-sig-
naling cascade but not of theTLR2-signaling cascade.One such
candidate is MD2, as the transfer of LPS monomers to MD2 is
essential for the induction of cellular signaling by the
TLR4MD2 receptor complex, whereas it is not required for
TLR2-dependent signaling (33). Furthermore, a hydrophobic
cavity has recently been identified in a proposed structure of
MD2 that is similar to that of CD14 and LBP (37), both of which
have been shown to bind OxPAPC (17). For this reason we
examined the potential of OxPAPC to competitively inhibit
LPS binding toMD2. In co-precipitation assays of supernatants
from HEK-293 cells expressing FLAG-tagged MD2 protein,
biotinylated LPS efficiently recov-
ered MD2 from the medium,
whereas this was reduced by com-
petitive inhibition with unlabeled
LPS or 50 g/ml OxPAPC (Fig. 9,
A and B). Next, in immunoassays
of mammalian cell-expressed
recombinant MD2 bound to
enzyme-linked immunosorbent
assay plates, OxPAPC, but not
native PAPC, was found to inhibit
the binding of biotinylated LPS to
MD2 in a dose-dependent fashion
(Fig. 9C). Finally, it has been estab-
lished that cells expressing TLR4
in the absence of MD2 are insensi-
tive to LPS and that LPS sensitivity
can be restored by supplementa-
tion with soluble MD2 before LPS
challenge or with preformed
LPSMD2 complexes (38). As
expected, HEK-293 cells express-
ing TLR4 in the absence of MD2
FIGURE 4. Effects of OxPAPC on intracellular signaling intermediates.
A, THP-1 macrophages were challenged with medium alone (Ctrl), 250 ng/ml
TNF-, or 10 ng/ml LPS with or without 50 g/ml OxPAPC co-treatment for 20
min before lysis. IB and glyceraldehyde-3-phosphate dehydrogenase
(GAPDH) content of lysates were measured by Western blot. B, alternatively,
J774A.1 cells were challenged with medium alone (DMEM, 1% FCS), 10 ng/ml
Pam3CSK4, 10 ng/ml LPS, or 1 g/ml flagellin in the presence or absence of 50
g/ml OxPAPC beforemeasurement of IB degradation and p38MAPK phos-
phorylationat20min.C, J774A.1cellswerechallengedwith1mMloxoribine (Lox)
or10g/mlCpGDNAwithorwithout50g/mlOxPAPCco-treatment for20min
before lysis. Results shown are representative of at least three experiments.
FIGURE 5. Effect of serum on cytokine induction by ligands of TLRs 2, 3, 4, and 5. A and C, washed THP-1
macrophages were challenged with the indicated concentrations of Pam3CSK4 or LPS in the presence or
absence of 1% serum. Supernatant TNF- was measured at 4 h. B, HASMC production of IL-8 in response to
poly(IC) with or without serumwasmeasured at 18 h.D, J774A.1macrophages were challengedwith flagellin
withorwithout serum, andTNF-wasmeasuredat 4h. Results shownare themeansof triplicate culturesS.D.
and are representative of at least three similar experiments. **, p 0.01 versuswith serum (ANOVA).
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co-transfection were insensitive to LPS but responded with
increased NF-B reporter activation in response to chal-
lenge with pre-assembled LPSMD2 complexes. However,
when complexes were prepared in the presence of both
OxPAPC and LPS, increased re-
porter activation was not observed
(Fig. 9D).
Effects of Specific Phospholipid
Oxidation Products on TLR2
Signaling—Because OxPAPC is a
mixture of phospholipid oxidation
products, we aimed to establish
which products of PAPC oxidation
may contribute to the inhibition of
TLR2 signaling. Unoxidized PAPC,
dipalmitoyl phosphatidylcholine,
arachidonic acid, and lysophos-
phatidyl choline did not inhibit
TLR2 signaling in transfected HEK-
293 cells (Fig. 10A). Electrospray
mass spectrometry of OxPAPC
revealed a similar pattern of oxida-
tion products to that described pre-
viously (4, 28), including products
such as POVPC (m/z 594.4) and
PGPC (m/z 610.4), which have been
characterized previously (Fig. 10B)
(4). POVPC and PGPC prepared by
total organic synthesis significantly
inhibited Pam3CSK4-induced TLR2
signaling, and LPS induced TLR4
signaling at concentrations 20
g/ml (30 M, Fig. 10, C and D).
Effects of OxPAPC on TLR2-de-
pendent Inflammation in Vivo—To
confirm that the effects of OxPAPC
on TLR2-dependent signaling
observed in vitro were relevant in
vivo, two murine models of TLR2-
dependent inflammation were
examined. BALB/c mice were
injected subcutaneously with 50 l
of saline, Pam3CSK4, or Pam3CSK4
with OxPAPC, and skin around
each injection site was removed
after 24 h for assessment of extent of
inflammation. A dense inflamma-
tory infiltrate was observed, partic-
ularly around the subcutaneous adi-
pose tissue, in Pam3CSK4-injected
animals that was reduced with
OxPAPC co-treatment and absent
in saline-injected skin samples (Fig
11, A–C). Quantification of poly-
morphonuclear granulocyte (PMN)
influx into subcutaneous adipose
tissues revealed a significant reduc-
tion in PMN influx with OxPAPC
co-treatment (Fig 11D). In separate experiments the numbers
of cells present in peritoneal lavage fluid from mice that were
injected intraperitoneallywith saline, Pam3CSK4, or Pam3CSK4
with OxPAPC were counted after 24 h. Pam3CSK4 treatment
FIGURE 6. Effect ofmCD14 expression on cellular sensitivity to ligands of TLR 2, 3, 4, and 5.HEK-293 cells
were transfected with NF-B-sensitive reporter construct (pELAM), transfection-efficiency control construct
(pRL-TK), and TLR2 (A), no TLRs (B), TLR4MD2 (C), or TLR5 (D) with or without co-transfection with mem-
brane CD14. After 48 h transfected cells were challenged with indicated concentrations of Pam3CSK4,
poly(IC), LPS, or flagellin. NF-B-dependent reporter activation was measured at 18 h and normalized to
internal transfection efficiency control and is presented as -fold induction relative to control cultures
challenged inmedium alone. Means of triplicate cultures are presented S.D. and are representative of at
least three similar experiments. **, p  0.01 versus with CD14 (ANOVA).
FIGURE 7. Effects of serum, LBP, and sCD14 on OxPAPC inhibition of TLR signaling. HEK-293 cells were
transfected with NF-B-sensitive reporter construct (pELAM), CD14, transfection-efficiency control construct
(pRL-TK), and TLR2 (A, C, and D), or TLR4MD2 (B). A and B, transfected cells were challenged with 100 ng/ml
Pam3CSK4 or 1 ng/ml LPSwith or without 30g/ml OxPAPC in DMEM supplementedwith 1, 10, or 30% serum.
Alternatively, TLR2 transfectants were challenged with 100 ng/ml Pam3CSK4 and 30 g/ml OxPAPC in 1%
serum in the presence or absence of 0.5 or 2.0 g/ml recombinant sCD14 (C) or 0.3 or 1.0 g/ml LBP purified
from human plasma (D). NF-B-dependent reporter activation was measured at 18 h, normalized to internal
transfection efficiency control, and is presented as -fold induction relative to control cultures challenged in
medium alone.Means of triplicate cultures are presented S.D. and are representative of at least three similar
experiments. **, p 0.01 versus PAMP without OxPAPC (ANOVA).
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increased the number of cells pres-
ent in peritoneal lavage fluid, and
this increase was significantly
reduced by OxPAPC co-treatment
(Fig 11E).
DISCUSSION
The oxidation of host phospho-
lipids by activated phagocytes is a
common consequence of inflamma-
tory events (3–6). Although many
studies have focused on the poten-
tial ofOxPLs generated by these and
other processes to potentiate fur-
ther pro-inflammatory mecha-
nisms, such as the induction of IL-8
secretion or increased adherence of
monocytes to endothelial cells (4, 8),
more recent studies have identified
numerous anti-inflammatory and
protective pathways triggered by
OxPLs (14–17). Together, these
findings have led to the proposal
that OxPLs may act as endog-
enously generated negative regula-
tors of inflammatory signaling, par-
ticularly via their potent inhibition
of LPS signaling (17). However,
although the mechanisms by which
OxPLs inhibit LPS-induced TLR4
signaling have been well studied,
much less is known of the roles of
OxPLs in the regulation of signaling
initiated by other TLRs. In the
absence of such studies and because
most of the TLRs share very similar
intracellular signaling pathways, it
has been assumed by many
researchers that OxPLs are likely to
be inhibitors of all TLRs (24, 39).
Contrary to this expectation,
however, we found that in a range of
cell types and using a variety of
markers of inflammatory signaling,
OxPAPC inhibited only TLR2- and
TLR4MD2- dependent signaling
but not signaling initiated by other
TLRs. We note that it has been sug-
gested previously that OxPAPC
may additionally inhibit CpG-
DNA-induced IB phosphoryla-
tion and TNF- production from
murinemacrophages via TLR9 (24).
However, we found that the high
concentrations of OxPAPC used in
this earlier study (100–300 g/ml)
caused a significant loss of viability
in THP-1macrophages (Fig. 8), sug-
FIGURE 8. Effect of membrane cholesterol-disrupting agents on TLR signaling and cellular viability.
THP-1macrophages were exposed to indicated concentrations ofmethyl--cyclodextrin, nystatin, or OxPAPC
for 18 h before assessment of cellular viability by MTT assay (A and B). Alternatively, THP-1 macrophages were
challenged with medium, 10 ng/ml Pam3CSK4 (C), or 10 ng/ml LPS (D) in the presence or absence of indicated
concentrations of membrane cholesterol-disrupting agents methyl--cyclodextrin or nystatin. Supernatant
TNF-wasmeasured at 4 h. Means of triplicate cultures are presentedS.D. and are representative of at least
three similar experiments. **, p 0.01 versus untreated cells (ANOVA).
FIGURE 9. Effect of OxPAPC on binding of LPS to MD2. A, supernatant of cells transfected with MD2-FLAG was
exposed tobiotinylated LPS (B-LPS)withorwithout 15minpreincubationwithunlabeled LPSor 50g/mlOxPAPC.
LPS-MD2 complexeswere precipitatedwith streptavidin-agarose beads, resuspended in SDS-PAGE loadingbuffer,
and separated on 15% SDS-PAGE gels before transfer to nitrocellulose blots. PrecipitatedMD2was visualizedwith
anti-FLAG antibody. B, mean intensity of precipitated MD2 bands was determined by densitometry from three
experimentsS.D.,p0.01(**)andp0.001(***)versuscontrol (Ctrl) (ANOVA).C, recombinanthumanMD2-FLAG
wasbound to immobilized anti-FLAGantibody, blockedwithbovine serumalbumin, andwashed. Biotinylated LPS
was then allowed to bind to boundMD2 in the presence or absence of the indicated concentrations of OxPAPC or
native (unoxidized) PAPC. Relative capture of biotinylated LPSwas quantified via binding of streptavidin-horserad-
ish peroxidase binding to wells as measured by absorbance at 450 nm after the addition of 3,3,5,5-tetramethyl-
benzidine. **,p0.01versusnativePAPC (nPAPC)-treated (ANOVA).D,HEK-293cells expressingNF-Breporterand
TLR4withoutMD2were exposed tomedium (Ctrl), LPS,MD2 supernatant,MD2 supernatant exposed to LPS for 30
min, or MD2 supernatant exposed to 50g/ml OxPAPC for 30min before the addition of LPS for a further 30min.
Activation of reporterwasmeasured at 18 h as described above and analyzed byANOVA. Results shown are repre-
sentative of at least three similar experiments.
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gesting that the effects observed by this groupmay be related to
nonspecific effects of OxPAPC toxicity at high concentrations
rather than direct inhibition of TLR9 signaling.
The present study also confirms and extends the observa-
tionsmade by other groups that intracellular signaling interme-
diates downstream fromTLR4 or receptors sharing similar sig-
naling pathways are not obviously inhibited by OxPAPC (11,
17, 24). For example, the observation that p38MAPKphospho-
rylation or IB degradation induced by ligands of TLRs 5, 7, 8,
or 9 is unaffected by OxPAPC (Fig. 4) suggests that OxPAPC
does not mediate anti-inflammatory effects via modulation of
thesemediators. Nevertheless, it should be noted that in certain
cell types, such as dendritic cells, OxPAPCmay exert immuno-
suppressive effects independently of its effects on direct inhibi-
tion of TLR-signaling pathways (25).
It has been suggested that themechanism bywhichOxPAPC
inhibits TLR signaling could involve the disruption of lipid-
rafts or raft-like caveolae in endothelial cells (11). This follows
the well established observation that stimulation of TLR4MD2
by LPS leads to the rapid recruitment of TLR4MD2LPS com-
plexes to the lipid raft fraction of cell membranes (36, 40), and
the resulting suggestion that recruitment to rafts may be a
requirement for, rather than merely a consequence of ligand-
induced TLR signaling (26, 36). A key contributor to the evi-
dence supporting this hypothesis is the demonstration that
raft-disrupting agents nystatin and MBCD-blunted TLR2- or
TLR4-dependent signaling in macrophages and Chinese ham-
ster ovary cells (26, 36). However, we found that the concentra-
tions of raft-disrupting agents that were used in these studies
(80Mnystatin or 10mMMBCD(26, 36)) induce a considerable
degree of toxicity in THP-1 macrophages (Fig. 8). Using suble-
thal concentrations of these agents, we saw no evidence of inhi-
bition of TLR2 or TLR4 signaling, whereas previous studies
showed that the use of MBCD at similar concentrations (0.5–
1.25 mM) led to efficient lipid raft disruption (41, 42). Thus,
further studies will be required to clarify whether recruitment
of TLRs to rafts is merely a consequence or a requirement of
ligand-inducedTLR-signaling. Likewise, further studiesmay be
FIGURE10.Effectsofmolecular speciespresent inOxPAPConTLR2andTLR4signaling.A, HEK-293cells expressingTLR2andNF-B reporterwereexposed
to 50 ng/ml Pam3CSK4 and 30 g/ml unoxidized PAPC, dipalmitoyl phosphatidyl choline (DPPC), arachidonic acid (AA), lysophosphatidylcholine (Lyso PC), or
OxPAPC. B, positive-ion electrospray mass-spectrometry of OxPAPC revealed a mixture of phospholipid oxidation products including POVPC and PGPC.
C, effects of POVPC and PGPC on HEK-TLR2 responses to 50 ng/ml Pam3CSK4. D, effects of POVPC and PGPC on HEK-TLR4 responses to 10 ng/ml LPS. Results
shown are representative of at least three similar experiments. **, p 0.01 versus cells cultured with TLR-agonist in absence of lipid (ANOVA).
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warranted to investigate whether the production of ceramide
by OxPAPC-challenged cells could contribute to TLR inhibi-
tion (27, 43), as ceramide has structural similarities to LPS and
has been proposed to act as either an agonist or antagonist of
LPS signaling under different conditions and in different cell
types (44–46).
In addressing potential mechanisms for the specificity of
TLR inhibition by OxPAPC, we found that although the pres-
ence of serum or expression of mCD14 is required for cellular
sensitivity to the TLR2 and TLR4 ligands Pam3CSK4 and LPS,
they are not required for signaling via TLR3 or TLR5. Notably,
it has been established that OxPAPC binds to serum accessory
proteins such as LBP and CD14 and competitively inhibits the
binding of LPS to these proteins (17). Likewise, it has been
shown that both di-acyl and tri-acyl bacterial lipopeptides bind
to CD14 and LBP (35, 47) and that CD14 and LBP are required
for enhanced cellular sensitivity to bacterial lipopeptides (32,
34). Thus, it is likely that the established binding of OxPAPC to
CD14 and LBP (17) also contributes to the inhibition of cellular
responsiveness to lipopeptides via TLR2. Supportive of this
conclusion is our observation that supplementationwith excess
serum, CD14, or LBP reversed OxPAPC inhibition of TLR2
(Fig. 7).
Interestingly, such treatments did not reverse OxPAPC inhi-
bition of LPS signaling (Fig. 7). This observation suggests that
an alternative site of inhibition, beyond serum components,
may additionally be involved in the inhibition of LPS signaling
and that this target may be cell-bound. We present evidence
here that, like LBP and CD14, OxPAPCmay also competitively
inhibit the binding of LPS to MD2, which is not required for
TLR2-dependent signaling. Although this inhibition was rela-
tively modest and required relatively high concentrations of
OxPAPC in our binding experi-
ments (Fig. 9, A–C), this could
reflect the nonphysiological origin
and setting of the recombinant
MD2 used in these experiments (i.e.
in the absence of binding partner
TLR4), as functional studies with
MD2 in the presence of cell-ex-
pressed TLR4 showed a clearer
inhibitory effect (Fig. 9D). Such a
mechanism is not without prece-
dent, as established inhibitors of
LPS signaling, such as penta-acyl
lipid A, Porphyromonas gingivalis
LPS and the drug Eritoran have each
been shown to mediate their inhibi-
tion of LPS signaling via competitive
interaction with MD2 (37, 48–50).
Thus, the model we propose is that
the mechanisms by which OxPLs
inhibit TLR signaling are similar to
those of lipid A-related antagonists
of TLR4, such that the main targets
for competitive inhibition are
CD14, LBP, and MD2. Because
thesemolecules are not required for
signaling by TLRs other than TLR2 and TLR4, this provides an
explanation for the specificity of OxPL-mediated inhibition of
TLRs.
Our efforts to identify specific phospholipid oxidation prod-
ucts present in OxPAPC that may contribute to TLR2 inhibi-
tion established that two prominent lipids present in OxPAPC,
POVPC and PGPC, are each capable of inhibiting TLR2- and
TLR4-dependent signaling at concentrations20 g/ml (30
M). Interestingly, other workers showed previously using elec-
trospray ionization-mass spectrometry methods that POVPC
and PGPC can reach concentrations of 40–60 g/g of tissue
during inflammation in rabbits (4). Thus, it is possible that the
specific components ofOxPAPC that we have identified to pos-
sess TLR inhibitory potential may reach concentrations suffi-
cient to inhibit TLR2 and TLR4 function in vivo. Accordingly,
we confirmed that OxPAPC inhibits TLR2-dependent inflam-
matory responses in vivo (Fig. 11) in a manner similar to that
seen with LPS challenge of mice (17).
The relevance of the specificity of OxPAPC inhibition for
only TLR2 and TLR4 remains to be established. Notably,
ligands ofTLR2 andTLR4 are normally encountered during the
course of bacterial or fungal infections, whereas viral infections
are typically thought to involve stimulation of other TLRs, such
as TLRs 3, 7, or 8 (51). Thus, it is tempting to speculate that
whereasOxPAPCmay act as an efficient negative feedback reg-
ulator of inflammation during bacterial or fungal infections,
this regulatory mechanismmay not equally apply to viral infec-
tions. Accordingly, mice deficient in functional NADPH oxi-
dase, a key contributor to reactive oxygen species formation by
phagocytes and potentially therefore inflammation-induced
OxPL formation, show exaggerated and temporally extended
inflammatory responses to challenge with the TLR2 stimulant
FIGURE 11. Effects ofOxPAPConTLR2-dependent inflammation in vivo. BALB/cmicewere injected subcu-
taneously with 50 l of saline (A), 2.5 g of Pam3CSK4 (B), or 2.5 g of Pam3CSK4 with 7.5 g OxPAPC (C). The
skin around each injection site was removed after 24 h, and extent of inflammatory infiltrate was assessed by
H&E staining (n 3 per group). The arrow indicates dense inflammatory infiltrate around subcutaneous adi-
pose tissue in Pam3CSK4-treated animals. D, polymorphonuclear granulocyte influx into subcutaneous adi-
pose tissue was counted in eight low power fields (mean  S.D. shown). E, in separate experiments, BALB/c
mice were injected intraperitoneally with 200 l of saline, 10 g of Pam3CSK4 (Pam3), or 10 g of Pam3CSK4
with 50 g of OxPAPC (n 4 per group). Cells were counted in peritoneal lavage fluid after 24 h.
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heat-killed Aspergillus fumigatus (52). Zymosan, also a TLR2
ligand, iswidely used to promote the development of arthritis in
mice, and it was shown that deficiency in NADPH oxidase also
leads to excessive tissue damage in amurinemodel of zymosan-
induced arthritis (53). Together, these findings suggest that
phagocyte-derived oxidants may play a role in the negative
feedback or resolution of inflammation that is distinct from
their role in killing microbes. Indeed, several of the properties
of OxPAPC, such as the nonphlogistic recruitment of mono-
cytes, inhibition of TLR signaling, and the induction of heme
oxygenase-1 expression are all consistent with a role in the pro-
motion of resolution. The possibility that OxPLs may serve as
mediators in this process is further supported by the recent
identification of OxPLs as mediators of the anti-inflammatory
properties of long wave ultraviolet radiation, which is used to
treat inflammatory disorders of the skin (7).
In summary, the present studies establish that, contrary to
expectation, OxPAPC is an inhibitor of only TLR2- and TLR4-
dependent signaling, that this is mediated largely via interac-
tion with accessory molecules including CD14, LBP, andMD2,
and that this inhibition does not extend to other TLRs. Further
examination of the anti-inflammatory properties and mecha-
nisms of OxPLs could provide useful information for the devel-
opment of novel therapeutic approaches to the treatment or
prevention of TLR-mediated inflammatory diseases.
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